H.C. Wainwright analyst Ed Arce maintained a Hold rating on Dicerna Pharma (NASDAQ: DRNA) today and set a price target of $14. The company’s shares opened today at $14.80, close to its 52-week high of $15.80.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 20.8% and a 42.6% success rate. Arce covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Conatus Pharmaceuticals, and Aurinia Pharmaceuticals.
Dicerna Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $14.
See today’s analyst top recommended stocks >>
Based on Dicerna Pharma’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $15.58 million. In comparison, last year the company had a GAAP net loss of $14.2 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company. It is focused on the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases using its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas.
Read More on DRNA:
